TMS 2026: Stephanie Faubion, MD, on how to identify overlooked menopause symptoms and guide hormonal or nonhormonal treatment ...
Only 21.7% of more than 318 000 women initiated systemic hormone therapy (HT) within 12 months of a natural menopause ...
Nearly 67% of US women receiving elinzanetant achieved at least a 50% reduction in menopausal VMS frequency by week 12 in ...
Stephanie Faubion, MD, on how to identify overlooked menopause symptoms and guide hormonal or nonhormonal treatment decisions ...
Maki, PhD, explains that OPTION-VMS provided reassuring news about the safety of fezolinetant (Veozah): No new or emerging ...
JoAnn Pinkerton, MD: Elinzanetant is a dual neurokinin receptor inhibitor. It's an NK1 and NK3 receptor antagonist, and what ...
OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and ...
Women who reported more frequent physical activity experienced significantly lower perimenopause symptom burden across ...
Pauline Maki, PhD, discusses real-world OPTION-VMS data linking fezolinetant to improvements in menopausal VMS, depression, ...
Women receiving menopause hormone therapy (HT) alongside semaglutide experienced significantly greater weight loss than those ...
Women who reached menopause before age 40 years had a higher long-term risk of cardiovascular disease (CVD) and coronary ...
Women with moderate to severe vasomotor symptoms (VMS) who received elinzanetant (Lynkuet; Bayer) were more likely than those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results